TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06425913

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Taping (KT)
Description: KT was applied to the symptomatic shoulder at the end of the baseline assessment by a certificated physiotherapist with over ten years of experience in Kinesio taping. After three days, participants were re-evaluated. KT application has been made according to the protocol for rotator cuff impingement or tendonitis including inhibition and correction techniques.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold Therapy (CT)
Description: The initial application was administered by the physiotherapist. In a sitting position, a pack was wrapped in a thin towel and placed on the affected shoulder joint, including the painful locations. During the application, the participant was closely observed for discomfort or adverse reactions (redness, burning, numbness, itching, ...). The cold application was continued for 20 minutes.After the first application, participants were instructed to apply ice for 20 minutes five times a day for three days at home or work.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standardized home exercise program
Description: All participants performed standardized home exercise program, including shoulder isometric and stretching exercises were . A physiotherapist taught the exercise program until the participants were able to exercise accurately on their own. All participants were instructed to perform the exercises three times a day for three days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standardized home exercise program
Description: All participants performed standardized home exercise program, including shoulder isometric and stretching exercises were . A physiotherapist taught the exercise program until the participants were able to exercise accurately on their own. All participants were instructed to perform the exercises three times a day for three days.
Study: NCT04744948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill exercise
Description: high intensity interval training

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: low caloric diet
Description: low caloric diet (1200ca/lday)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low caloric diet
Description: low caloric diet (1200ca/lday)
Study: NCT06422624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Extended-release for Injectable Suspension, 1 mg
Description: Singel-dose; Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Extended-release for Injectable Suspension, 4 mg
Description: Singel-dose; Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Extended-release for Injectable Suspension, 8 mg
Description: Singel-dose; Subcutaneous
Study: NCT06005012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) that is FDA-approved for the treatment of obesity (as Wegovy) or T2DM (as Ozempic).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05482945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noble gas Argon
Description: Ventilation with Ar 70%/O2 30% in comatose patients resuscitated from OHCA with the use of an experimental mechanical ventilator.
Study: NCT05664204

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Veno-arterial extracorporeal membrane oxygenation
Description: Strategy would reduce the need for invasive mechanical ventilation in the first 28 days without increasing adverse events

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Veno-arterial extracorporeal membrane oxygenation
Description: Strategy would reduce the need for invasive mechanical ventilation in the first 28 days without increasing adverse events
Study: NCT05352347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NuSepin® 0.4 mg/kg
Description: NuSepin® 0.4 mg/kg in 100mL NS bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (NS) 100mL bid
Study: NCT05062902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device
Description: A personalized, precision botulinum neurotoxin injection guidance medical device, utilizing an intra-vaginal high-density surface EMG system to optimize the treatment outcomes in chronic pelvic pain (CPP) management.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Neurotoxin
Description: Botulinum neurotoxin will be injected into the pelvic floor muscles following either a standard template (standard injection arm), or guided using high-density surface EMG (guided arm).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Neurotoxin
Description: Botulinum neurotoxin will be injected into the pelvic floor muscles following either a standard template (standard injection arm), or guided using high-density surface EMG (guided arm).
Study: NCT05243953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levcromakalim
Description: Study participants will be allocated to receive continuous intravenous infusion of 0.05 mg/min (20 ml of 50 mg/ml) levcromakalim.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
Study: NCT06260332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Care (Fitbit)
Description: Wear Fitbit, Use Fitbit application, Receive educational materials, attend coaching calls, Ancillary studies
Study: NCT04709913

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HU6
Description: HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HU6
Description: HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
Study: NCT05438264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: acetylcholinesterase inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT05829304

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MTA based pulpotomy
Description: The principal investigator will carry out all treatment procedures, and the patients will be assigned. It will be as split mouth, both groups A\&B will be at the same patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MTA based pulpotomy
Description: The principal investigator will carry out all treatment procedures, and the patients will be assigned. It will be as split mouth, both groups A\&B will be at the same patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collagen based pulpotomy
Description: The principal investigator will carry out all treatment procedures, and the patients will be assigned. It will be as split mouth, both groups A\&B will be at the same patient.
Study: NCT06452368

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: facemask
Description: Fixation of miniplates by four screws in the maxilla and protraction by using facemask

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: facemask
Description: Fixation of miniplates by four screws in the maxilla and protraction by using facemask
Study: NCT05829304

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collagen based pulpotomy
Description: The principal investigator will carry out all treatment procedures, and the patients will be assigned. It will be as split mouth, both groups A\&B will be at the same patient.
Study: NCT06271382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure Group
Description: In the research, the participant in the acupressure group will receive acupressure application 3 times a week for 2 weeks, a total of 6 times.~Depending on the preparation and pressure time on the 5 selected points (a total of 10 points will be applied since the partner of each point on the other extremity will be applied), the session duration for an individual will be approximately 18-20 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acupressure Group
Description: Depending on the preparation and pressure time on the 5 selected sham points (a total of 10 points will be applied since the partner of each point on the other extremity will be applied), the session duration for an individual will be approximately 18-20 minutes.~Patients in the sham acupressure group will receive acupressure 6 times in total, 3 times a week for 2 weeks. The practitioner will do the first acupressure at the Family Health Center, and the person with type 2 diabetes will do the others at home. Ankle Brachial Index evaluation will be performed by the researcher at the Family Health Center a total of 3 times before the intervention, 1 week after the intervention and 2 weeks after the intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot Ankle Exercise Group
Description: Exercise will be performed regularly for 2 weeks, 3 days a week for a maximum of 30 minutes.
Study: NCT05297799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ameda Pearl breast pump
Description: The Ameda Pearl breast pump is a powered, multi-user breast pump with stimulation and expression modes and independently user-selectable speed and suction control in each mode.
Study: NCT05619003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biatain Silicone Sacral dressing
Description: Biatain Silicone Sacral will be applied over the bony prominence of the sacral area
Study: NCT04913571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab
Study: NCT04636190

Intervention type: DEVICE
Group type: OTHER
Intervention: Triathlon All-Polyethylene Tibia Knee
Description: Triathlon All-Polyethylene Tibia Knee is an all polyethylene resurfacing knee device using either a condylar stabilizing (CS) and posterior stabilizing (PS) device.
Study: NCT05375370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: circulating tumor DNA dosage
Description: blood sample for circulating tumor DNA dosage will be done to patient with hepatocellular carcinoma
Study: NCT05678270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-192
Description: ICP-192 is a round, uncoated tablet, 5mg, orally.
Study: NCT04773288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Live feedback during handwashing
Description: Live feedback provided during handwashing on display
Study: NCT05509062

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure
Description: Subjects are randomized to one of three treatment groups

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure
Description: Subjects are randomized to one of three treatment groups
Study: NCT06149689

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX plus radiotherapy
Description: Patients with advanced pancreatic adenocarcinoma will receive a modified FOLFIRINOX regimen (oxaliplatin \[70 mg per square meter of body surface area\], irinotecan \[130 mg per square meter\], leucovorin \[200 mg per square meter\], and fluorouracil \[2000 mg per square meter\] every 2 weeks). Four-week chemotherapy is considered as a cycle. Patients will be recommended to receive Intensity-Modulated Radiation Therapy (IMRT) after about 4\~6 cycles of chemotherapy. The following treatment after radiotherapy will be applied according to the newest edition of National Comprehensive Cancer Network (NCCN) guideline.
Study: NCT05509062

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure
Description: Subjects are randomized to one of three treatment groups
Study: NCT05939245

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Furosemide Injection
Description: Continuous infusion of furosemide is administered starting at 2 mg/hour and can be titrated until the target urine output of 1-2 cc/kg/hour is achieved for 48 hours. In case of hypotension (MAP \<65 mmHg), norepinephrine is administered with titration starting at a dose of 0.05 mcg/kg/minute, along with a fluid loading of 4 cc/kg body weight or 300 cc within 5-10 minutes, until the target MAP of ≥65 mmHg is reached for 48 hours.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: Continuous infusion of placebo fluid is administered at a rate of 2 mL/hour. In case of hypotension (MAP \<65 mmHg), norepinephrine is administered with titration starting at a dose of 0.05 mcg/kg/minute, along with a fluid loading of 4 cc/kg body weight or 300 cc within 5-10 minutes, until the target MAP of ≥65 mmHg is reached for 48 hours.
Study: NCT05365789

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blocked Nose Baby nasal spray
Description: One or two nasal sprays will be administered to each nostril for a minimum of 2 times per day up to a maximum of 6 times per day for a maximum of 10 days.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Standard of care consists of hydration, rest at home and antipyretic paracetamol as necessary.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care consists of hydration, rest at home and antipyretic paracetamol as necessary.
Study: NCT06493643

Intervention type: OTHER
Intervention: Measurement of perfusion index after supraclavicular brachial plexus block at blocked & unblocked limb
Description: The PI (Perfusion Index) was measured using Masimo SET pulse oximetry applied on the index finger. The PI was recorded at baseline and at 10 , 20 , and 30 min after local anaesthetic injection in both the blocked limb and the contralateral unblocked limb using two separate oximeters. The PI ratio was calculated as the ratio between the PI at 10min after injection and the baseline PI. In every patient, a comparison between the blocked and unblocked limb was performed .
Study: NCT06130098

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Training by the clinical nurse before discharge. Prepare an educational brochure and give it to patients. Application of patient information form, EQ-5D-5L Quality of Life and OKS Scale During the routine check-up in the first week, evaluates the development of complications without knowing which group the patient is in.~Within the first week and at the end of the fourth week, the wound site is evaluated by the physician for the development of complications, . Patients who cannot come for a check-up should send a photo of the wound area to the researcher via WhatsApp application, and the photo will be forwarded to the clinician who performed the surgery and the physician will record the complication situation. It is planned to receive complication development and wound site evaluation results from the physician system.~At the end of the fourth and sixth weeks after discharge, the EQ-5D-5L and OKS scale must be filled in again by the patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: experimental group
Description: Providing training before discharge Prepare an educational brochure and give it to patients. You will be contacted by phone at the end of the first, second, third and fourth weeks after discharge.~Application of patient information form, EQ-5D-5L Quality of Life and OKS Scale Evaluating the wound site in terms of complications within the first week and at the end of the fourth week. It is planned to receive complication development and wound site evaluation results from the system.~After the first check-up, calling the patients in the study group at the end of the first week after discharge.~Providing training on the subjects included in the training brochure in the first phone call and recording any existing problems.~In the fourth meeting, tele-nursing service will be provided through the Telephone Counseling Protocol.~EQ-5D-5L and OKS forms must be filled out again by patients at the routine check-up at the end of the fourth and sixth weeks after discharge.
Study: NCT05703425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Sulfasalazine will be administered between 24 and 36 weeks of pregnancy
Study: NCT04762992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous Enoxaparin
Description: Enoxaparin subcutaneous injections (40 mg, 4000 IU daily) starting immediately after the diagnosis of FGR, and until 36 weeks of gestation or 12 hours before delivery, whichever comes first.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard of care
Description: Obsteric standard of care.
Study: NCT06402929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Honest Open Proud - College (HOP-C)
Description: The program consists of three weekly workshops that are two hours in duration. There is a fourth booster workshop (two hours in duration) one month following program completion. All workshops will be held over an online videoconferencing platform.~HOP-C is a group program led by trained peer facilitators who have lived mental illness experience. Major topics that the program covers are:~1. discussing different types of disclosure;~2. conducting a cost-benefit analysis of disclosing in different situations;~3. strategies to anticipate how certain people will respond to disclosure when deciding on who to disclose to;~4. disclosure via social media; and~5. a guided creation of participants' own disclosure narrative.~During the booster workshop, participants will be encouraged to reflect on their disclosure decisions, and periodically revisit their disclosure cost-benefit analysis in deciding if and when to disclose in the future.
Study: NCT06145659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preschool and Me
Description: Utilizes patient navigation services and a medical-educational care plan to support linkages between medical and educational systems
Study: NCT05568160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: The infusion is started at 5 ml hr-1, increased in increments of 1 ml hr-1 every 5 minutes to reach a maximum target rate of 30 ml hr-1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: The infusion is started at 5 ml h-1, increased in increments of 1 ml h-1 every 5 minutes to a maximum target rate of 30 ml h-1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collection of clinical data
Description: At D1, D2, D7, D30 or D60 and D90

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of clinical data
Description: At D1, D2, D7, D30 or D60 and D90

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life Questionnaire EQ-5D
Description: At the anesthesia consultation, discharge from intensive care, D7, D30 and D90

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaire EQ-5D
Description: At the anesthesia consultation, discharge from intensive care, D7, D30 and D90
Study: NCT05013021

Intervention type: OTHER
Group type: OTHER
Intervention: Sprint Interval Training
Description: The Sprint Interval Training (SIT) training consists of 3 successive blocks of 5 training sessions each. The sessions are 24 to 48 hours apart.~. One block lasts two weeks. After the end of one block, the following block begins the day after.~The Sprint Interval Training lasts 6 weeks.~Each session consists of a series of sprints, the number of which varies from 8 to 14. Thus a session will last from 30 to 45 min approximately~So, the time frame of this study is Baseline, Block 1, Block 2 and Block 3 (Not in day or week or month)
Study: NCT06063265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Attention Training Program
Description: Integrated Attention Training Program (IATP) specifically aims at training attentional control, which involves the coordination of complex behaviours, such as planning, reasoning, selection and information inhibition.
Study: NCT05376527

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double Recombinant Vaccinia Virus VV-GMCSF-Lact
Description: Intratumoral injections:~1\*107 PFU (calculated at minimal ED on mice); 2\*107 PFU; 4\*107 PFU; 6\*107 PFU; 8\*107 PFU; 10\*107 PFU;
Study: NCT04584931

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronally advanced flap
Description: flap surgery to achieve root coverage at gingival recession defect

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: restorative intervention
Description: colored composite restoration to camouflage the gingival recession defect
Study: NCT05013697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib
Description: TQB2450 injection: 1200 mg, i.v.gtt , d1;Anlotinib 10mg, po.qd , d1-14；Paclitaxel 135mg/m2, i.v.gtt , d1; Cisplatin 60-75mg/m2, i.v.gtt , d1-d3; The above schemes are repeated every three weeks. After 4-6 cycles, the regimen is changed to Anlotinib (10mg, po.qd , d1-14)+TQB2450 injection（1200 mg, i.v.gtt , d1）. The regimen is repeated every 3 weeks until the disease progresses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Cisplatin + TQB2450 injection
Description: TQB2450 injection: 1200 mg, i.v.gtt , d1;Paclitaxel 135mg/m2, i.v.gtt , d1; Cisplatin 60-75mg/m2, i.v.gtt , d1-d3; The above schemes are repeated every three weeks. After 4-6 cycles, the regimen is changed to TQB2450 injection（1200 mg, i.v.gtt , d1）. The regimen is repeated every 3 weeks until the disease progresses.
Study: NCT05843305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-452080
Description: Subjects will receive BPI-452080 until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-452080
Description: Subjects will receive BPI-452080 until disease progression
Study: NCT06074549

Intervention type: DEVICE
Intervention: DynamX Novolimus-eluting Coronary Bioadaptor System
Description: All patients will receive at least one DynamX Bioadaptor implant in a commercial setting in accordance with the product's Instructions for Use